201 results about "Cisplatin" patented technology

The invention discloses a traditional Chinese medicine composition, a preparation method thereof and an application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating ovarian reserve hypofunction, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of radix paeoniae alba, 6 to 10 parts of radix bupleuri, 10 to 15 parts of radix rehmanniae preparata, 15 to 30 parts of stir-fried rhizoma dioscoreae, 12 to 20 parts of semen cuscutae, 10 to 12 parts of radix angelicae sinensis, 10 to 15 parts of poria cocos, 12 to 25 parts of fructus ligustri lucidi, 10 to 15 parts of radix salviae miltiorrhizae, 10 to 15 parts of fructus corni and 10 to 15 parts of radix morindae officinalis. The traditional Chinese medicine composition can obviously reduce the level of follicle-stimulating hormone (FSH) of cis-platinum model mice, increase estradiol (E2), increase the number of follicles at all levels, especially the number of primordial follicles, and reduce the number of atresia follicles; the ovarian function of naturally aged mice can be improved, FSH (follicle stimulating hormone) is reduced, anti-mullerian hormone (AMH) and E2 are increased, and the quantity of follicles at all levels, especially the quantity of corpus luteum, primordial follicles and anterior sinus follicles, is increased; therefore, the composition disclosed by the invention has an obvious protection effect on the hypoovarian reserve function.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

Compositions of particles having at least 95% by weight of cisplatin and a specific surface area (SSA) of at least 3.5 m2 / g. methods for their use. and methods for their production are provided.

The application belongs to the technical field of antitumor drugs, and discloses an iron complex as well as a preparation method and application thereof.The preparation steps of the iron complex are as follows: 1, reacting 2-hydrazinylbenzothiazole, a ketone compound and a solvent to obtain a ligand; and 2, reacting the ligand, ferric chloride and a solvent, and then cooling and crystallizing to obtain the iron complex.The obtained iron complex can effectively induce cancer cell ferroptosis, can effectively inhibit the growth of breast cancer, lung cancer, liver cancer or glioma, has high selectivity, has small toxicity to normal cell strains, and has better treatment effect compared with existing clinical drugs, such as cisplatin.

The application discloses an 8-hydroxyquinoline anticancer zinc (II) complex and a synthesis method and application thereof. The 8-hydroxyquinoline anticancer zinc (II) complex is synthesized by taking 5,7-diiodo-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, 5-chloro-7-iodo-8-hydroxyquinoline, 5,7-dibromo-8-hydroxyquinoline and 5-chloro-8-hydroxyquinoline as a first ligand and taking 4,4'-dimethoxy-2,2'-bipyridine, 4,4-di-tert-butyl-2,2-bipyridine, 5,5'-dimethyl-2,2-bipyridine, 2,2-bipyridine and 4,4'-dimethyl-2,2'-bipyridine as auxiliary ligands. The 8-hydroxyquinoline anticancer zinc (II) complex has good inhibiting effect on SK-OV-3CR cells of an ovarian cancer drug-resistant strain, is higher than that of cisplatin drugs, overcomes drug resistance of clinical drugs, has potential medicinal value and can be used for preparation of various antitumor drugs.

The application belongs to the technical field of nanomedicine, tumor treatment and immunotherapy, and specifically provides a copper death selective induction nanoparticle targeting tumor mitochondria, which is prepared by the following preparation method: S1, TPY is specifically coupled with MHI through a condensation reaction to obtain MTPY; S2, MTPY is complexed with copper ions to obtain an MTPY-Cu complex; and S3, the MTPY-Cu complex is self-assembled with albumin to form an MTPY-Cu@Alb nanoparticle. The copper dose of the application is only 1 / 1000 of that of free Cu 2+ , and the equivalent immune regulation and killing effects can be achieved; the primary tumor and distant tumor foci can be inhibited, and lung metastasis can be reduced; and the application can induce immune memory and prevent recurrence; the application is combined with cisplatin to significantly enhance the therapeutic effect and reverse the induced immunosuppression; and the application has high biological safety, and has no obvious hepatorenal toxicity or hemolytic reaction.

The application discloses application of Ophisaurus apodus in preparation of a drug for reversing drug resistance of gastric cancer and belongs to the technical field of medicines. The application can reduce tumor volume and size, promote drug resistance cell apoptosis, and reverse the chemotherapeutic drug resistance of a nude mouse with gastric cancer by jointly using Ophisaurus apodus in different parts of the body and cisplatin, by down-regulating P-gp, MRP1 and Bcl-2 protein expression, and by up-regulating Bax protein expression. The effect of the tail + cisplatin group is the most significant.

The invention discloses application of cucurbitacine I in preparation of cisplatin sensitization drugs for treating ovarian cancer, and belongs to the technical field of sensitization drugs for tumor chemotherapy. CuI and CDDP have a good synergistic tumor inhibition effect on ovarian cancer, CuI may directly act on EGFR and can be combined with CDDP to significantly inhibit phosphorylation of EGFR and downstream STAT3 protein thereof, induce DNA damage and ROS accumulation, amplify a pyroptosis effect, increase release of TAAs and DAMPs, promote DC maturation and promote infiltration of CD8 + T cells and memory T cells in TIME in vivo, so that the tumor inhibition effect on ovarian cancer is improved. The expression of an inhibitory costimulatory molecule PD-1 in CD8 + T cells is reduced, the whole body immune effect is activated, and the TIME of the ovarian cancer is remarkably improved. The combined treatment strategy of CuI-CDDP controls the progress of ovarian cancer from a dual mechanism of directly inhibiting tumor cells and promoting anti-tumor immune activation.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

The application relates to an application of a drug for preventing and treating deafness in preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective component of the drug for preventing and treating acute kidney injury caused by cisplatin is prepared from raw medicinal materials in the following weight percentage: 27-33% of ginseng, 16-20% of astragalus, 16-20% of pueraria, 11-13% of curcuma, 12-15% of platycodon, and 8-10% of licorice. The drug for preventing and treating acute kidney injury caused by cisplatin in the application can obviously reduce the creatinine and urea nitrogen levels, improve the morphological damage of kidney tissues, and has a remarkable effect on preventing and treating acute kidney injury caused by cisplatin.

The application discloses a kind of 2-triazole ethane-1-ketone / alcohol HSP90 / HIF-1 inhibitor and application, new drug use technical field.This kind of inhibitor is transformed from 7-hydroxy new piece helicon A, can low toxicity efficiently inhibit the expression of HIF-1, inhibit tumor cell invasion, clonal proliferation and other malignant development process, in vivo anti-tumor activity experiment and cisplatin can effectively inhibit tumor.This kind of inhibitor can be applied to the preparation of inhibiting cancer development drug.

The application provides a benzyl chromone compound and a preparation method and application thereof. The application takes dry fruit bodies of Leucangium alectorium as raw materials, carries out ethanol extraction, ethyl acetate extraction, then carries out rough separation on the ethyl acetate phase obtained by extraction with different proportions of dichloromethane-methanol solution, and then carries out elution separation with different proportions of methanol-water to obtain a novel structure benzyl chromone compound. The benzyl chromone compound provided by the application has significant in-vitro inhibition activity on HepG2 cell proliferation, and when the treatment concentration is below 160 muM, the inhibition activity on liver cancer cells is obviously better than that of cisplatin, and the benzyl chromone compound can be used for preparing drugs for treating and preventing liver cancer. Meanwhile, the raw material of the compound is rich in source, low in price, simple in preparation process and convenient for industrial application, so the discovery of the compound is expected to provide a promising treatment scheme for liver cancer patients, and has great significance for breaking through the bottleneck of liver cancer treatment.

The application discloses application of MNT in detection of ferroptosis and chemotherapy sensitivity of lung adenocarcinoma. The application is based on a series of molecular biology experiments, and reveals that high expression of MNT inhibits ferroptosis of lung adenocarcinoma and increases chemotherapy sensitivity. Based on the results of the molecular biology experiments, the application first proposes a new use of MNT in detection of ferroptosis and chemotherapy sensitivity of lung adenocarcinoma; the expression amount of MNT of lung adenocarcinoma is detected to judge the sensitivity of lung adenocarcinoma patients to ferroptosis inducer and chemotherapy treatment, and the method has the advantages of simple operation, high sensitivity, specificity, high cost performance and application value, and provides a new way for clinically evaluating the sensitivity of lung adenocarcinoma patients to ferroptosis and cisplatin treatment.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

The invention discloses a preparation method and application of a coumarin-hydrazide-based semi-sandwich type iridium and ruthenium complex, the structural formula of the complex is as shown in formula (I), the complex takes a coumarin-hydrazide derivative as an NO bidentate ligand, and an oxygen coordination atom in the ligand is derived from hydroxyl of a coumarin mother nucleus; iridium or ruthenium is used as a metal center, benzene is used as a unique solvent, alkali does not need to be added additionally under the protection of nitrogen, and the ligand can be prepared through a coordination reaction of the ligand and a metal dimer. The complex shows good anti-cancer activity, the drug effect of the complex is close to that of cis-platinum, and the complex has the potential value of becoming a novel anti-cancer drug.

Described herein are methods of treating MTAP-null gastrointestinal cancer in a patient comprising administering to the patient a PRMT5 inhibitor, gemcitabine, and paclitaxel (e.g., nab-paclitaxel), or a PRMT5 inhibitor and mFOLFIRINOX. Also described herein are methods of treating MTAP-null gastrointestinal cancer in a patient comprising administering to the patient a PRMT5 inhibitor, gemcitabine, cisplatin, and an anti-PD 1 antibody or an anti-PDL1 antibody.

This invention provides the application of Lycium barbarum polysaccharide (LBP) in the preparation of drugs for the prevention or treatment of intestinal flora and metabolic disorders. Research results show that LBP can significantly improve cisplatin-induced intestinal microbiota and metabolic disorders in rats, manifested by a significant reduction in CDDP-induced serum AST and ALT levels, and improvement in the degree of liver tissue lesions. Furthermore, LBP did not exhibit toxicity in rats. LBP enhanced the diversity and richness of the gut microbiota, restored the structure of dominant symbiotic bacteria, inhibited the proliferation of potentially pathogenic bacteria, and promoted the enrichment of functional bacteria related to SCFAs generation. LBP also restored abnormal metabolism in branched-chain amino acid and aromatic amino acid metabolism, one-carbon metabolism, and lipid metabolism. This invention provides a theoretical basis for the application of natural active polysaccharides in the prevention and treatment of intestinal microbiota and metabolic disorders.

This invention discloses a novel class of β-carboline quaternary ammonium salt derivatives, their preparation methods, and applications. The derivatives have the structure shown in Formula I, where R1, R2, and R3 are various substituents, and X... ‑ It is a halide ion. Its preparation method uses substituted indole-2-methylamine and substituted α-haloacetophenone as starting materials, and constructs them through a one-step cyclization reaction in an aprotic solvent mediated by a catalytic protic acid (such as p-toluenesulfonic acid). This method is mild, simple to operate, requires no metal catalyst, eliminates the risk of metal residue, and has good functional group compatibility. Activity tests of the obtained series of compounds showed that they have significant inhibitory activity against the proliferation of non-small cell lung cancer cell lines (such as A549 and H1299), with some compounds exhibiting activity superior to the positive control drug cisplatin. Therefore, this compound has important application value in the preparation of antitumor drugs, especially anti-lung cancer drugs.

The invention discloses application of neoplasm vine and cis-platinum in preparation of a medicine for preventing and treating lung cancer. Belongs to the technical field of biological medicine. The invention finds that the synergy of the neoplasm vine ethyl acetate part extract and cis-platinum can effectively treat the non-small cell lung cancer, the mechanism has the characteristics of multiple components, multiple targets and multiple pathways, and the PI3K / AKT / mTOR signal pathway may be one of the therapeutic action pathways of the PI3K / AKT / mTOR signal pathway.

The present application belongs to the technical field of biological medicine, and particularly relates to Hermetia illucens extract, an extraction method thereof and application thereof in preventing and treating tumors. The present application extracts polar components from Hermetia illucens powder, and the obtained Hermetia illucens extract has a significantly better inhibitory activity on the proliferation of Cal27 human tongue squamous cell carcinoma cells, Colo205 human colorectal cancer cells and U87 MG human brain astrocytoma cells than the Hermetia illucens powder without separation under the same mass concentration. In animal experiments, the Hermetia illucens extract can significantly prolong the survival cycle of MOC-1 tongue squamous cell carcinoma mice, and has a significantly better treatment effect than the Hermetia illucens powder and is close to the positive drug cisplatin.

The application discloses application of a rehmannia glutinosa extract in preparation of drugs for treating kidney injury caused by cisplatin. The application of the rehmannia glutinosa extract in preparation of drugs for preventing and / or treating kidney injury caused by cisplatin; a preparation method of the rehmannia glutinosa extract, comprising the following steps: S1, adding water to the rehmannia glutinosa to perform extraction, to obtain a rehmannia glutinosa water extract; S2, adding ethyl acetate to the rehmannia glutinosa water extract to perform extraction, separating ethyl acetate phase and water phase, to obtain the rehmannia glutinosa extract. The application constructs an animal model by inducing mouse kidney injury by cisplatin, and it is found that the rehmannia glutinosa extract obtained by further separating the rehmannia glutinosa water extract by using solvents such as ethyl acetate and ethanol can improve acute kidney injury caused by cisplatin, and the effect is better than that of the rehmannia glutinosa water extract.

The invention discloses an application of circRNA (Ribonucleic Acid) molecules for detecting and treating gastric signet ring cell carcinoma. The invention provides a substance taking circUBR5 as an inhibition target and application of cis-platinum in preparation of a medicine for treating gastric cancer. The invention also provides an application of a substance taking circUBR5 as an inhibition target in preparation of a medicine for treating gastric cancer. The invention finds that the circUBR5 can inhibit the proliferation, migration and invasion of gastric cancer cells, thereby inhibiting the growth and metastasis of gastric cancer tumors. The invention finds that the substance for inhibiting circUBR5 and cis-platinum can be jointly used for treating gastric cancer and have a more obvious effect. The invention has application and popularization values for treatment of gastric cancer (especially gastric signet ring cell carcinoma).

The application discloses a kind of 8-hydroxyquinoline-pyridine anticancer zinc (II) complex preparation and application, belong to medical technology field, solve the technical problem of drug resistance of prior art in cisplatin, the method is as follows: Zn (NO3) 2·6H2O, methanol and dichloromethane mixed solution and second ligand are mixed in pressure tube, and cover tightly cover, under 60-70 ℃ 3 days, after reaction, cooling to room temperature, first ligand and triethylamine are added to pressure tube, place in closed environment, under 75-85 ℃ 3 days, cooling to room temperature and stationary, obtain target complex. 50 It is found that the complex has good inhibitory effect on SK-OV-3 / DDP, the IC 50 value is 1.45-10.14 μM, and the toxicity to normal cells HL-7702 is very small, which shows that the complex has selectivity to tumor cells SK-OV-3 / DDP, overcomes the drug resistance of clinical drug, has potential medicinal value, and is expected to be used for the preparation of various antitumor drugs.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

The invention discloses a preparation method and application of a semi-sandwich type iridium complex containing a tridentate ligand. The structural formula of the complex is shown as a formula (I), a ligand and a dimer react under the reaction condition, sodium bicarbonate is continuously added into a reaction system, proton H on coumarin unit carbon in the ligand can be selectively removed, and therefore the semi-sandwich type iridium complex (I) of the CNS tridentate ligand is obtained. Wherein a coordination carbon atom (C, blue) in the tridentate chelate ligand is derived from a coumarin unit, a nitrogen atom (N, red) is derived from a Schiff base structure, a sulfur atom (S, pink) is derived from thiosemicarbazide, the obtained iridium complex shows good anticancer activity, the performance of the iridium complex is close to or even superior to that of commercial cis-platinum, and the iridium complex is a very potential anticancer drug.

A method of treating a COVID-19 infection includes administering to a subject in need thereof an effective amount of a composition, where the composition includes silica nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), chitosan, cisplatin, ribavirin, and an angiotensin-converting enzyme 2 (ACE-2). The SPIONs and ACE-2 are dispersed on an outer surface of the silica nanoparticles. The chitosan at least partially wraps around the outer surface of the silica nanoparticles. The cisplatin and ribavirin are in pores of the silica nanoparticles. The composition is in the form of particles that are monodisperse, are spherical, and have an average diameter of 70-100 nanometers (nm).

The invention relates to a pegylated cis-platinum compound as well as a preparation method and application thereof, and belongs to the technical field of drug carriers. The pegylated cis-platinum compound is obtained through covalent coupling of polyethylene glycol and cis-platinum. The invention provides a novel pegylated cis-platinum compound and a preparation method thereof, a pharmaceutical composition containing the pegylated cis-platinum compound and a preparation of the pharmaceutical composition, and particularly relates to a nucleic acid pharmaceutical composition containing the pegylated cis-platinum compound and a preparation of the nucleic acid pharmaceutical composition. The nucleic acid medicine composition preparation can deliver the nucleic acid medicine into cells, the transport rate of the nucleic acid medicine is increased, toxicity is reduced, and therefore the treatment effect of the nucleic acid medicine is improved.

The application discloses a virus-mimic drug carrier targeting tumor stem cells and a preparation method and application thereof. The drug carrier can improve cell uptake efficiency by simulating physical surface characteristics of a biological system and can directly target tumor stem cells. In addition, the drug carrier can protect healthy tissues due to the targeting property, significantly reduce side effects of high-dose single use of a loaded drug such as PTC209, effectively enhance the response to tumor stem cells, inhibit tumor proliferation and metastasis, and reduce drug resistance of combined use of drugs such as cisplatin.

The invention discloses a novel prolyl hydroxylase 2 and histone deacetylase 6 dual selective inhibitor as shown in a formula I as well as a preparation method and application thereof, and the prolyl hydroxylase 2 and histone deacetylase 6 dual selective inhibitor plays a role in relieving acute kidney injury caused by cis-platinum by simultaneously inhibiting the activity of prolyl hydroxylase (PHD2) and histone deacetylase 6 (HDAC6). The compound is expected to become a novel acute kidney injury treatment medicine.

The application discloses a kind of block copolymer and its preparation method and application, the application designs and synthesizes a kind of block copolymer mPEG-PLG-COOH-CD, utilize the host molecule β-CD with guest molecule IDO-1 inhibitor (such as Epa) and Pt class chemotherapy drug (such as cisplatin) with large cavity structure, by hydrophilic and hydrophobic interaction, host-guest recognition, coordination effect common assembly into supramolecular nanomedicine.Supramolecular nanomedicine simultaneously carries Pt class chemotherapy drug and IDO-1 inhibitor.Under the action of weak acid in tumor cell, nanomedicine swells, expose drug, and high concentration of Cl- will destroy the non-covalent bond force inside nanomedicine, quickly release chemotherapy drug and IDO-1 inhibitor, while activating chemotherapy and immunotherapy, realize the efficient combination of two kinds of therapy.In situ activation of chemotherapy not only directly kills cancer cells, but also activates the anti-tumor immunity of body.